Portfolio Choice     

Published: February 28, 2025
Updated: February 28, 2025

DEEPAK NITRITE
BSE ticker code 506401
NSE ticker code DEEPAKNTR
Major activity Speciality Chemicals
CMD Deepak C. Mehta
Equity capital Rs 27.28 crore; FV Rs 02
52 week high/low Rs 3169 / Rs 1810
CMP Rs 1922.75
Market Capitalisation Rs 26224.97 crore
Recommendation Buy
Smorgasbord of speciality chemicals

Headquartered at Vadodara (Gujarat), Deepak Nitrite Ltd (DNL) is a multi-division and multi product chemical intermediates manufacturer engaged in manufacturing chemical intermediaries, fine and speciality chemicals, products and phenolics. It has a wide portfolio of over 100 products, with leader ship in the majority of its products. The company’s manufacturing fa cilities are located at Nandesari and Dahej in Gujarat, Roha and Taloja in Maharashtra, and Hyderabad in Telangana.

Deepak Nitrite’s products have several use cases, such as in colourants, petrochemicals, rubbers, adhesives, personal care, thinners, ply, laminates and foundry. The com pany enjoys a 75 per cent marketshare in sodium nitrite and nitrotoluenes in India. It also has an over 50 per cent marketshare in phenol and acetone. It can boast of over 1,000 customers in India as well as in Europe, the US, Asia and the Middle East.

The company has made rapid strides on the financial front, with its sales turnover during the last 10 years ex panding almost six times from Rs 1,327 crore in fiscal 2015 to Rs 7,682 crore in fiscal 2024, operating profit shooting up around eight times from Rs 140 crore to Rs 1,127 crore, and the profit at net level surging over 15 times from Rs 53 crore to Rs 811 crore. However, as with other chemical companies, Deepak’s sales and earnings have been adversely affected in the recent downturn. But it is widely believed that the downward drift will not per sist for a long time and the revival will began within the next few years. Consider:

  • Chemicals have become essential to modern life, impacting almost everything from the food we eat and the clothes we wear to the medicines we use and the electronics we depend on. This pervasive role cannot remain neglected for a long time. Little wonder that the prices of chemical stocks have suffered a severe setback, with the Deepak Ni trite stock tumbling from Rs 3,169 to Rs 1,898 during the last 12 months. But these low levels have started attracting institutional investors. For example, mutual funds’ stake in DNL, which was less than 8 per cent in February 2023, has shot up to around 12 per cent by now.
  • CHINA FACTOR
  • Many of the company’s existing products are fac ing keen and uneven competition from Chinese exports. Now, Deepak has introduced new products with higher margins. The impact of this exercise will be visible from the next quarter.
  • The company has embarked upon an ambitious capital expenditure plan to set up new projects. The nitric acid project is fast coming up and is expected to be commissioned in the next quarter, while MIBK/MIBC and acetophenone projects are likely to go on stream in the first half of fiscal 2026. Other projects like nitration and hydrogenation will come online in the second half of 2026. The management has guided to com plete all the polymer-related projects by December 2027. The full benefits from these projects will be visible from 2028 onwards.
  • The company’s financial position is extremely sound, with reserves at the end of March 2024 standing at Rs 5,061 crore — 185 times its tiny equity capital of Rs 23 crore. DNL is a debt-free entity as it has repaid all its debt obligations in the five-year period upto 2023.
  • STOCK SCENE
  • Thanks to oversupply and dumping from China, the share price has nosedived sharply from its all-time high of Rs 3,169 reached in 2024 to Rs 1,810. But these lower levels have started attracting investment, leading to a hike in the price to Rs 1,898. Research analysts believe that the price will gradually go up. Though there is a downside risk, discerning investors will do well to accumulate this stock at every decline.

PERFORMANCE INDICATORS (Rs. in crore)

Year Net Sales Net Profit EPS (Rs.) Div (%) BV (%)
2023-24 7681.83 727.65 53.30 375.00 373.10
2024-25 (E) 7840.50 780.15 54.70 375.00 380.40
2025-26 (E) 8139.17 825.40 57.10 385.00 385.29
ASTER DM HEALTHCARE
BSE ticker code 540975
NSE ticker code ASTERDM
Major activity Hospital
Chairman Mandayapurath Azadmoopen
Equity capital Rs 499.51 crore; FV Rs 10
52 week high/low Rs 559 / Rs 312
CMP Rs 410.45
Market Capitalisation Rs 20502.51 crore
Recommendation Buy
Kerala’s undisputed healthcare king

Aster DM Healthcare is one of the largest integrated healthcare service providers in the Middle East and an emerging player in India. It has op erations in seven countries, including GCC and India. Its integrated model covers the entire life cycle of healthcare — from primary to quaternary — through its state-of-the art hospitals, clinics and pharma ceuticals. The company is focused on expansion via an asset-light model (1,000 beds through O&M) in India. The management is tar geting an India expansion with low capex investment but high poten tial opportunity.

Aster’s network consists of 13 hospitals, 109 clinics and 240 retail pharmacies in the GCC states, and 14 hospitals, 11 clinics, 131 phar macies and 141 laboratories in In dia, with total bed capacity being 460 in GCC and 3,905 in India.

The company is doing quite well on the financial front. During the last 12 years, sales have almost doubled from Rs 7,922 crore in fiscal 2013 to Rs 3,699 crore in fiscal 2024, with operating profit more than doubling from Rs 261 crore to Rs 575 crore, and the profit at net level inching up from Rs 149 crore to Rs 212 crore. What is more, prospects for the company going ahead are all the more promising. Con sider:

KOCHI EXPANSION
  • The company is in expansion mode. Recently, As ter Medicity at Kochi inaugurated its fourth tower, which added 100 beds to the hospital in order to meet rising de mand. With the launch of this fourth tower, Aster Medicity, which is Kerala’s first JCI-accredited quaternary care and multi-speciality hospital, marked a significant milestone. This tower spans 1 lakh sq ft with 100 new beds, meeting the growing needs of the region.
  • Since its inception, the 40-acre waterfront campus has played a pivotal role in transforming medical value tour ism in Kerala, including high-precision robotic surgery us ing the da Vinci surgery system.
  • Expansion of beds by 34% in FY27: The com pany plans to add beds capacity of 1677 beds over a span of 3 years which will increase the number of beds by 34% from 4,867 beds in FY24 to 6,544 beds in FY27E with total capex spend of Rs. 11 Bn. Aster DM will be adding 959 beds through brownfield expansion across its hospitals in Kerala, Karnataka, and Andhra Pradesh hospitals with capex of Rs 4.8n over FY24 27E. Further company is looking to add additional 718 beds through greenfield in Kasaragod and Trivandrum (Kerala) with expected capex spend of Rs. 5.7 Bn. Since, Aster already has strong presence in all three regions it won't be difficult for them to attract patients due to strong regional connect. This will help to boost revenue growth going forward. The capex will largely be funded by internal accruals as the company has healthy cash flows. Despite large capex cycle, the returns ratios are expected to improve for the company with ROE and ROCE of 12% and 13% respectively in FY27E.
  • Aster DM Healthcare has taken a major decision to merge with Quality Care backed by Blackstone. The merger makes the combined entity the third largest healthcare chain by revenue and bed capacity in India. Little wonder that the news of the merger pushed up the stock price as the merger will boost the topline as well as bottomline of the company. The combined entity will have a network of 38 hospitals and 10,150+ beds, spread across 27 cities. Research analysts at Elara Securities be lieve that the transaction will position the combined en tity as the undisputed leader in corpo rate healthcare in Kerala. Little wonder that leading brokerages have rated the scrip a ‘BUY’ with a target price of Rs 550. Prabhudas has recommended ‘BUY’ with a target price of Rs 620. The stock is quoted today around Rs 396.

PERFORMANCE INDICATORS (Rs. in crore)

Year Net Sales Net Profit EPS (Rs.) Div (%) BV (%)
2023-24 3698.90 125.84 2.50 20.00 60.40
2024-25 (E) 3850.40 128.40 2.65 20.00 62.75
2025-26 (E) 4160.40 135.54 2.85 25.00 66.46
SIGNPOST INDIA
BSE ticker code 544117
NSE ticker code SIGNPOST
Major activity Advertising & Media Agencies
Chairman Girish Pandurang Kulkarni
Equity capital Rs 10.69 crore; FV Rs 02
52 week high/low Rs 461 / Rs 212
CMP Rs 251.95
Market Capitalisation Rs 1346.67 crore
Recommendation Buy
Pole player in outdoor advertising

Mumbai-headquartered Signpost India is a small cap player providing both static and digital OOH (out of house) advertising services. Since inception in 2008, it has emerged as a leading outdoor advertising solutions provider that cre ates advertising properties around public convenience utili ties, including airports, metros, bus shelters and city roads, and uses them for display of advertisements through design, technology, data analytics and content provision. With demon strable experience, the company engi neers end-to-end mega projects to build public places that ensure com muters’ convenience, ergonomic and transparent roofing and priority seat ing, tactile flooring, accessibility ramp, charging stations, SOS integration, mapped surrounding lavatories, au thority notifications of upcoming buses, and much more. The company has re ceived awards in numerous categories, including 57 gold, 43 silver and 28 bronze, including prestigious ones like ABBYs, ENVIEs, Lon don Digital Signage, and Kyoorius Dragon of Asia.

Signpost has clients in multiple industries, including con sumer goods and services, BFSI, lifestyle, real estate and con struction, media, entertainment, education, pharma, telecom, automobiles and hospitality, as well as in government minis tries.

It has steadily grown on the financial front since incep tion in 2008 and after its listing in 2021. During the last three years (after it got listed on BSE and NSE), revenues have expanded from Rs 168 crore in fiscal 2022 to Rs 338 crore in fiscal 2023 and further to Rs 387 crore in fiscal 2024, with the profit at net level shooting up from Rs 8 crore in fiscal 2022 to Rs 3 crore in fiscal 2023 and further to Rs 44 crore in fiscal 2024. Signpst’s financial position is very strong, with reserves at the end of March 2024 standing at Rs 205 crore — over 18 times its tiny equity capital of Rs 11 crore. What is more, prospects going ahead are all the more promising. Consider:

    VETERAN TEAM
  • The company has a strong standing in its field on account of the extensive experience of its promoters and management team. The two decade-long experience of the promoters in outdoor media publicity has helped the com pany establish strong relationships with large advertisers on a pan-India basis and garner a strong market position. The Signpost group is expected to con tinue receiving strategic guidance from the promoters, while it also has a professional management team for overseeing various functions. All the directors are veterans with over two decades of experience in the indus try.
  • Signpost’s strong mar ket position is well reflected in its established position across several formats and consistent growth. The company has been expanding its presence across locations, including Mumbai, Delhi, Bangalore, Chennai, Kolkata, Nagpur, Pune, Nashik and Aurangabad.
  • The company is known for its healthy operating effi ciency. Signpost has economical advertising properties in prime locations across various places such as skywalks, BQs, foot overbridges, sell-service bicycle systems, city information pan els, mobile charging terminals, digital innovations at airports, and prominent public places. This provides an edge over the competition for better pricing and occupancy. Little wonder, it recently won several new contracts, such as Mumbai BQs, Mumbai Metro and Delhi Aerocity. It is also focusing on digital assets, which have a higher margin, and on reducing its share of the trading business, which has lower margin. This practice has resulted in improvement in the overall operating margin to 23 per cent in fiscal 2023, against 14 per cent in fiscal 2022. Margins are expected to be healthy going ahead. The Signpost stock had going strong at around Rs 450 of late. But on account of the distinctly bearish trend it has fallen back to around Rs 247. Observers strongly feel that once the market turns steady, Signpost will be among the first stocks to resume its upward journey.

PERFORMANCE INDICATORS (Rs. in crore)

Year Net Series Net Profit EPS (Rs.) Div (%) BV (%)
2023-24 387.45 41.20 7.70 25.00 40.40
2024-25 (E) 405.45 42.40 7.90 25.00 41.50
2025-26 (E) 424.50 40.70 8.45 30.00 43.70

March 15, 2025 - First Issue

Industry Review

VOL XVI - 12
March 01-15, 2025

Formerly Fortune India Managing Editor Deven Malkan Assistant Editor A.K. Batha President Bhupendra Shah Circulation Executive Warren Sequeira Art Director Prakash S. Acharekar Graphic Designer Madhukar Thakur Investment Analysis CI Research Bureau Anvicon Research DD Research Bureau Manager (Special Projects) Bhagwan Bhosale Editorial Associates New Delhi Ranjana Arora Bureau Chief Kolkata Anirbahn Chawdhory Gujarat Pranav Brahmbhatt Bureau Cheif Mobile: 098251-49108 Bangalore Jaya Padmanabhan Bureau Chief Chennai S Gururajan Bureau Chief (Tamil Nadu) Ludhiana Ajitkumar Vijh Bhubaneshwar Braja Bandhu Behera

Want to Subscribe?


Lighter Vein

Popular Stories

E-Waste Dilemma Tackling E-Waste Via Reverse Logistics, By Vihaan Shah

A modern-day enigma and a ramification of humanity's never-ending advancements, e-waste refers to the scum con- cealed by the outward glow of ever-advancing technology.

Archives

About Us    Contact Us    Careers    Terms & Condition    Privacy Policy

Liability clause: The investment recommendations made here are based on the personal judgement of the authors concerned. We do not accept liability for any losses that might occur. All rights reserved. Reproduction in any manner, in whole or in part, in English or in any other language is prohibited.

Copyright © 1983-2025 Corporate India. All Rights Reserved.

www.corporateind.com | Cookie Policy | Disclaimer